Compare GLPI & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLPI | ASND |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 15.2B |
| IPO Year | 2013 | 2014 |
| Metric | GLPI | ASND |
|---|---|---|
| Price | $44.65 | $244.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $51.95 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 2.5M | 473.2K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | ★ 2.79 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $1,594,752,000.00 | N/A |
| Revenue This Year | $9.17 | $96.35 |
| Revenue Next Year | $5.40 | $44.91 |
| P/E Ratio | $27.70 | ★ N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $41.17 | $175.19 |
| 52 Week High | $49.95 | $282.15 |
| Indicator | GLPI | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 40.32 |
| Support Level | $43.97 | $213.28 |
| Resistance Level | $45.93 | $249.89 |
| Average True Range (ATR) | 0.85 | 7.65 |
| MACD | 0.11 | -2.77 |
| Stochastic Oscillator | 35.17 | 14.13 |
Gaming and Leisure Properties Inc, or GLP, is a self-administered and self-managed Pennsylvania real estate investment trust (REIT). It is engaged in acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. The company also extends loans that produce fixed or variable returns, which may convert into leased rent upon project completion or stabilization. Its portfolio consists of gaming and related facilities and amenities such as Ameristar Black Hawk, Bally's Casino, Argosy Casino Alton, Bally's Chicago, Hollywood Casino Aurora, and others located across different states in the United States.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.